First look at how kidneys handle promising hepatitis d treatment
NCT ID NCT05760300
Summary
This early-stage study tested how the hepatitis D drug bulevirtide behaves in people with different levels of kidney function. Researchers gave the drug to 41 people, some with healthy kidneys and some with impaired kidney function. They measured how much drug got into the blood, how the body processed it, and checked for safety to see if dosing needs adjustment for people with kidney problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS D INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advanced Pharma CR, LLC
Miami, Florida, 33147, United States
-
Clinical Pharmacology of Miami, LLC
Miami, Florida, 33014, United States
-
Floridian Clinical Research, LLC
Miami Lakes, Florida, 33016, United States
-
Genesis Clinical Research, LLC
Tampa, Florida, 33603, United States
-
Global Clinical Professionals Research
St. Petersburg, Florida, 33705, United States
-
Massachusetts General Hospital - Renal Associates Clinic
Boston, Massachusetts, 02114, United States
-
Nucleus Network
Saint Paul, Minnesota, 55114, United States
-
Panax Clinical Research
Miami Lakes, Florida, 33014, United States
-
Velocity Clinical Research, New Smyrna Beach
Edgewater, Florida, 32132, United States
Conditions
Explore the condition pages connected to this study.